BioXcel Therapeutics ^{Priced, Nasdaq: BTAI}

We are a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. Our drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. We believe that this differentiated approach has the potential to reduce the cost and time of drug development in diseases with substantial unmet medical need. BXCL501 is a sublingual thin film formulation of the a2a adrenergic receptor agonist dexmedetomidine, or Dex, for acute treatment of agitation resulting from neurological and psychiatric disorders. We intend to utilize the 505(b)(2) pathway for BXCL501, and initiated a Phase 1b safety study using the IV formulation of Dex in mild probable Alzheimer's Disease in December 2017, and plan to do the same for schizophrenia patients in the 1H18, with data expected in the 2H18. BXCL701 (formerly Talabostat) is an immuno-oncology agent for treatment of a rare form of prostate cancer and pancreatic cancer.